Micromet to Report Third Quarter 2010 Financial Results on November 9

BETHESDA, Md.--(BUSINESS WIRE)-- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced that it will host a conference call and audio webcast to review its third quarter 2010 results on Tuesday, November 9, 2010, at 8:30 AM ET.

To participate in the conference call, please dial 866-713-8395 (domestic) or 617-597-5309 (international) and reference the access code 11269684. The presentation will be available via webcast in the Investor Relations section of the Micromet website at www.micromet.com.

A replay of the call will be available from 11:30 AM ET on November 9, 2010 until midnight ET on December 9, 2010. To access the replay, please dial 888-286-8010 (domestic) or 617-801-6888 (international) and reference the access code 63331845. The archived webcast will be available for 30 days at www.micromet.com.

About Micromet, Inc.

Micromet, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibody-based therapies for the treatment of cancer. Its product development pipeline includes novel antibodies generated with its proprietary BiTE® technology, as well as conventional monoclonal antibodies. The Company’s lead product candidate blinatumomab (MT103) is currently the subject of a European pivotal trial in patients with minimal residual disease positive acute lymphoblastic leukemia. Micromet has collaborations with a number of leading pharmaceutical and biotechnology companies, including Bayer Schering Pharma, Boehringer Ingelheim, MedImmune, Merck Serono, Nycomed and sanofi-aventis. Additional information can be found at www.micromet.com.



CONTACT:

Micromet, Inc.
Jennifer Neiman
Director, Corporate Communications
240-235-0246
[email protected]

KEYWORDS:   United States  North America  Maryland

INDUSTRY KEYWORDS:   Health  Biotechnology  Oncology  Pharmaceutical  Research  Science

MEDIA:

Suggested Articles

Saturday, AstraZeneca revealed more of the data that convinced the FDA to green-light Calquence in previously untreated chronic lymphocytic leukemia.

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.